News tagged ‘TargetedTherapy’ clear
- Erica Mayer, MD, MPH, and colleagues are leading a pilot phase 2 clinical trial to test the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer.
Tags: BreastCancer, TargetedTherapy
- Dana-Farber researchers report new data point to the lasting benefit, for many patients, of the targeted drug imatinib which has revolutionized the treatment of advanced gastrointestinal stromal tumors.
Tags: Sarcoma, TargetedTherapy
- A study 10 years ago discovered a gene mutation that could be treated by a drug that was on the market for something else and changed the way lung cancer patients are treated. It was the start of the era of precision medicine in lung cancer and transformed treatment of the disease.
Tags: EGFR, LungCancer, TargetedTherapy
- Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a targeted drug for advanced stomach cancer.
Tags: chemotherapy, TargetedTherapy
- Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings, published in Nature Genetics, identify potential new targets for drug treatments.
Tags: ChildhoodCancer, Genomics, TargetedTherapy, BrainTumors
- A study by researchers at Dana-Farber Cancer Institute shows that not all doctors are ready to embrace tests that look for hundreds of DNA changes in patients' tumor samples, while others plan to offer this type of cancer gene testing to most of their patients.
Tags: Genomics, TargetedTherapy
- Genomic profiling of a patient's advanced bladder cancer explained his "exceptional response" to the drug everolimus. The scientists say this technique can help identify other patients who may respond to the drug.
- An analysis of clinical trial data led by Dana-Farber researches showed that patients with advanced kidney cancer lived an average of seven months longer if they were taking a common type of high blood pressure medication during treatment.
- Dana-Farber researchers have found that a combination of two already-in-use drugs may have an effect on stopping the growth of the most common genetic subtype of lung cancer setting the stage for clinical trials.
Tags: LungCancer, TargetedTherapy
- Scientists have identified a mutated gene that causes a type of benign brain tumor that can have devastating lifelong effects. It may be possible to attack the tumors with targeted drugs already in use for other tumors.
Tags: TargetedTherapy, BrainTumors
Showing 11-20 of 48 items